St. Jude Medical Inc. announced U.S. Food and Drug Administration (FDA) approval of the first-to-market MultiPoint Pacing technology featured on the Quadra line of cardiac resynchronization therapy defibrillators (CRT-D) and pacemakers.

By genetically reprogramming the most common type of cell in mammalian connective tissue, researchers at the University of Wisconsin-Madison have generated master heart cells — primitive progenitors that form the developing heart.

Researchers funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) used ultrasound-activated microbubbles to improve preservation of heart muscle and function in a pig heart attack model. Based on this success, the method is now in phase I human clinical trials.

February 10, 2016 — Fred Hoiberg, head coach of the National Basketball Assocation’s (NBA) Chicago Bulls, is launching a ...

CeloNova BioSciences Inc. announced this week that the first patient has been enrolled in its COBRA REDUCE trial. The COBRA REDUCE trial recently received conditional U.S. Food and Drug Administration (FDA) approval and will study the Cobra PzF nanocoated coronary stent (NCS) system in patients at high risk of bleeding.

In a finding that could lead to new drugs to treat heart failure, researchers have uncovered the molecular mechanism that regulates how the heart pumps blood.